Aernoud Fiolet

170 Chapter 6 Finally, we agree with D’Amario et al. regarding the relevance of the colchicine– platelet interaction as possibly contributing to the benefits of the drug in preventing major adverse cardiovascular events. As the correspondents note, we were unable to address this issue in our trial because we did not perform platelet- function testing. Aernoud T.L. Fiolet, M.D. University Medical Center Utrecht, Utrecht, the Netherlands Jan H. Cornel, M.D., Ph.D., Radboud University Medical Center, Nijmegen, the Netherlands Peter L. Thompson, M.B., B.S., M.D.University of Western Australia, Perth, WA, Australia REFERENCES: 1. Yusuf S, Wittes J. Interpreting geographic variations in results of randomized, controlled trials. N Engl J Med 2016;375:2263-2271. 2. Lagakos SW. The challenge of subgroup analyses — reporting without distorting. N Engl J Med 2006;354:1667-1669. 3. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 2000;343:475-480. 4. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010;3:135-142. 5. Ding EL, Powe NR, Manson JE, Sherber NS, Braunstein JB. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med 2007;167:905-912.